Format

Send to

Choose Destination
J Clin Aesthet Dermatol. 2018 Feb;11(2):47-52. Epub 2018 Feb 1.

Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey.

Zeichner JA1,2,3,4,5, Eichenfield LF1,2,3,4,5, Feldman SR1,2,3,4,5, Kasteler JS1,2,3,4,5, Ferrusi IL1,2,3,4,5.

Author information

1
Dr. Zeichner is with Mount Sinai Hospital in New York, New York.
2
Dr. Eichenfield is with the University of California and Rady Children's Hospital, both in San Diego, California.
3
Dr. Feldman is with the Wake Forest University School of Medicine in Winston-Salem, North Carolina.
4
Dr. Kasteler is with the University of Louisville in Louisville, Kentucky.
5
Dr. Ferrusi is with Allergan plc in Irvine, California.

Abstract

OBJECTIVE: The objective of the study was to evaluate the impact of rosacea on self-perception, emotional, social, and overall well-being and quality of life in individuals with erythematotelangiectatic rosacea (ETR) and papulopustular rosacea (PPR). DESIGN: We distributed a cross-sectional email invitation for participants in the United States to fill out a web-based survey. PARTICIPANTS: We included adults who reported having previously received a diagnosis of erythematotelangiectatic rosacea or papulopustular rosacea. MEASUREMENTS: Questionnaires measured the psychosocial aspects of rosacea, including the Satisfaction With Appearance Scale and modified Satisfaction With Appearance Scale questionnaires, Impact Assessment for Rosacea Facial Redness, Rosacea-Specific Quality-of-Life questionnaire, and RAND 36-Item Short Form Health Survey. The Impact Assessment for Rosacea Facial Bumps or Pimples was administered to the papulopustular rosacea cohort. RESULTS: Six hundred participants enrolled and completed the survey, with most rating their rosacea as mild or moderate (ETR: 95.6%; PPR: 93.7%). In the erythematotelangiectatic rosacea and papulopustular rosacea cohorts, respectively, 45 and 53 percent disagreed/strongly disagreed that they were satisfied with their appearance due to rosacea; 42 and 27 percent agreed/strongly agreed that they "worry how people will react when they see my rosacea"; and 43 and 59 percent agreed/strongly agreed that they feel their rosacea is unattractive to others. Rosacea-Specific Quality-of-Life total and domain scores indicated negative impact of rosacea for both cohorts. Both cohorts reported worse 36-item Short Form Health Survey overall and domain scores than population norms in the United States. CONCLUSION: Rosacea had wide-ranging, negative effects on self-perceptions and emotional, social, and overall well-being as well as rosacea-specific quality of life. Overall, both erythematotelangiectatic rosacea and papulopustular rosacea cohorts reported a substantial negative impact of rosacea on quality of life on a range of instruments.

KEYWORDS:

Rosacea; erythematotelangiectatic rosacea; papulopustular rosacea; psychosocial impact; quality of life

PMID:
29552276
PMCID:
PMC5843362

Conflict of interest statement

FUNDING:This study was sponsored by Allergan plc (Dublin, Ireland). DISCLOSURES:Dr. Zeichner has been an advisory board member, consultant, or speaker for Allergan, Bayer, Foamix, Galderma, Intraderm, Isdin, Janssen, Johnson and Johnson, L’Oreal, Novan, and Promius. Dr. Eichenfield has been a consultant and investigator for Allergan, Galderma, Novan, and Valeant. Dr. Feldman has been an investigator, speaker, and/or consultant for Abbvie, Advance Medical, Caremark, Celgene, Galderma, Janssen, Kikaku, Leo Pharma, Lilly, Merck, Mylan, Novartis, Pfizer, Qurient, Sanofi, Sienna, Sun Pharmaceuticals, Suncare Research, Taro, Valeant, and Xenoport. Dr. Feldman also owns stock in Causa Technologies and Medical Quality Enhancement Corporation, has received royalties from Informa, UpToDate, and Xlibris, and is Founder and Chief Technology Officer of Causa Technologies. Dr. Kasteler has been an investigator and a speaker for Allergan, Amgen, Bayer, Novartis, and Sun Pharmaceuticals, and has participated in advisory board meetings for Amgen, Bayer, and Sun Pharmaceuticals. Dr. Ferrusi was an employee of Allergan plc at the time the study was conducted.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center